Question special
Lead Moderator

Thanks to all who have contributed to the excellent discussion on the role of sequencing technology. It is clear that many patients are doing poorly due to unrecognised drug resistance as well as limited access to DR-TB drugs such as linezolid, bedaquiline and delamanid and other gaps in the DR-TB cascade of care. How should we approach patients with DR-TB who are currently failing therapy in terms of ongoing transmission?